GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

InBioGen Co 101140.KS · KRW

Consumer Discretionary · KRX · 🇰🇷 South Korea

Compare

4,875

+2.09%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩6.30bn

FY2016FY2025

Net income

−₩1.42bn

FY2016FY2025

Free cash flow

−₩5.60bn

FY2016FY2025

Shareholders' equity

₩157.64bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩6.30bn₩7.04bn₩6.24bn₩11.40bn₩10.48bn₩10.22bn₩9.80bn₩7.57bn₩7.08bn₩11.55bn
Research and development—₩21.9m₩8.2m₩3.7m₩24.6m—————
Operating income−₩4.33bn−₩6.09bn−₩6.14bn−₩5.93bn−₩7.69bn−₩5.41bn−₩1.67bn₩1.37bn−₩1.53bn−₩2.13bn
Net income−₩1.42bn₩16.12bn₩11.34bn−₩119.69bn₩94.12bn−₩45.08bn₩13.12bn₩1.66bn−₩1.21bn−₩2.26bn
Diluted earnings per share-36.75417.61293.84-3,100.182,438.06-1,167.62339.9468.33-51.23-112.66

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩159.99bn₩162.73bn₩151.31bn₩141.81bn₩274.47bn₩96.88bn₩90.92bn₩24.32bn₩13.39bn₩12.38bn
Total liabilities₩2.35bn₩2.89bn₩2.62bn₩37.40bn₩96.45bn₩18.97bn₩24.92bn₩968.8m₩2.07bn₩6.62bn
Debt——————₩9.52bn—₩357.9m₩2.57bn
Shareholders' equity₩157.64bn₩159.84bn₩148.68bn₩104.42bn₩178.02bn₩77.91bn₩66.00bn₩23.35bn₩11.32bn₩5.75bn
Shares outstanding39m39m39m39m39m39m39m24m24m20m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩5.55bn−₩33.1m−₩1.05bn−₩11.51bn−₩7.07bn−₩8.03bn−₩3.83bn−₩1.70bn−₩426.4m₩344.7m
Capital spending−₩42.5m−₩84.3m−₩331.0m−₩130.7m−₩2.36bn−₩427.9m−₩288.4m−₩288.4m−₩288.4m—
Free cash flow−₩5.60bn−₩117.4m−₩1.38bn−₩11.64bn−₩9.43bn−₩8.46bn−₩4.12bn−₩1.99bn−₩714.8m₩344.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩1.51bn₩786.3m₩660.6m₩2.15bn₩1.85bn₩1.64bn₩2.17bn₩2.08bn
Operating income−₩924.4m−₩979.7m−₩953.4m−₩1.05bn−₩1.00bn−₩1.32bn−₩2.12bn−₩1.34bn
Net income−₩1.48bn−₩14.68bn−₩12.74bn₩8.17bn₩1.12bn₩2.03bn₩14.80bn−₩4.42bn
Diluted earnings per share-38.22-380.20-330.12211.6529.1052.62383.34-114.50
Cash from operations−₩1.15bn−₩264.0m−₩549.0m−₩1.67bn−₩1.81bn−₩1.52bn₩1.35bn−₩576.0m
Capital spending—−₩46.0m—−₩4.0m−₩6.0m−₩32.0m−₩60.0m—
Free cash flow—−₩310.0m—−₩1.67bn−₩1.82bn−₩1.56bn₩1.29bn—
Total assets₩146.88bn₩148.33bn₩159.99bn₩173.22bn₩164.84bn₩164.08bn₩162.73bn₩152.34bn
Shareholders' equity₩141.50bn₩142.98bn₩157.64bn₩170.78bn₩162.56bn₩161.62bn₩159.84bn₩149.90bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-18.0%-9.2%-3.4%
Operating income-9.9%-4.3%-1.5%
Net income-77.2%-49.9%-13.0%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-78.1%-72.6%-68.9%-46.2%
Net margin110.2%-302.2%-86.3%-40.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-285.522.431.8-5.029.2-89.8175.6—-1038.5-363.9
Price to sales64.351.257.852.5262.3396.0235.3315.4177.771.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-0.05 reverse split · 21 Sept 2023
  • 2-to-1 reverse split · 25 Apr 2012
  • 10-for-1 split · 30 Sept 2008

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.